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ABSTRACT
We sought to determine whether wild-type hematopoietic cell transplantation directly into muscle could
restore dystrophin expression in a relevant preclinical canine model of Duchenne muscular dystrophy. In
recipients rendered tolerant to their dog leukocyte antigen-matched unaffected littermates through hemato-
poietic stem cell transplantation, intramuscular injection of donor marrow cells produced no evidence of
dystrophin expression, and clonal analysis of satellite cells failed to reveal any donor contribution.
© 2007 American Society for Blood and Marrow Transplantation
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hNTRODUCTION
Transdifferentiation of hematopoietic stem cells
nto muscle cells has been reported in animal models
1,2] and clinical practice [3,4]. This raised the potential
or therapeutic application in ischemic and degenerative
isorders of both skeletal and cardiac muscle. Limited
uccess with clinical trials suggested the need for pro-
ocative signals or improved homing to permit relevant
epopulation of affected muscle tissues. To overcome
igure 1. Chimerism analyses from peripheral blood, muscle biop
ntramuscular marrow injections from the unaffected HCT donor. A
15] that differentiated donor and recipient. Muscle biopsies demo
ematopoietic cells present in muscle tissue, whereas cultured satellite cel
86hese barriers, we employed a canine model of Duch-
nne muscular dystrophy (DMD) [5,6], a degenerative,
rogressive, and ultimately fatal muscle disorder [7,8]. In
umans, this disease affects 1 in 3500 male births, and
esults from a mutation in the gene encoding dystrophin
9], an essential component of striated muscle, leading to
yoﬁber injury, necrosis, and ﬁbrosis [10].
We previously reported the failure of allogeneic
ematopoietic cell transplantation (HCT) to result in
d cultured muscle satellite cells from a DMD-affected dog given
erformed by PCR ampliﬁcation of variable number tandem repeats
contribution from both donor and recipient representative of thesies, an
ssays p
nstratels failed to show donor contribution (PB, peripheral blood).
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Hematopoietic Cell Transplantation into Dystrophic Muscle 887econstitution of dystrophin expression in striated or
ardiac muscle in this canine model [11]. However,
his strategy has provided immune tolerance, which
ermitted transplantation of allogeneic donor tissue
hat expressed dystrophin in the form of isolated do-
or muscle ﬁbers [11] and vascularized muscle ﬂaps
data not shown). To gain further insight, we asked
hether direct injection of unmodiﬁed bone marrow
rom a healthy donor dog would yield dystrophin
xpression in affected DMD canine recipients.
Two littermate donor-recipient pairs with dog
eukocyte antigen (DLA) identity [12,13] were chosen
here the recipients possessed the dystrophin muta-
ion [14], and thus the DMD phenotype, whereas the
onors were either wild type or carrier littermates.
CT with myeloablative conditioning was performed
s previously described [11] and resulted in full and
ustained donor hematopoietic chimerism as assessed
y microsatellite marker polymorphism analyses [15]
Figure 1). More than 2 years after HCT, skeletal
uscle biopsies demonstrated no dystrophin expres-
ion above background. Four years after HCT donor
one marrow cells were collected by aspiration from
onor humeri, ﬁltered (100 m), and an average of
.19  106 nucleated cells (1% CD34 cells) were
njected directly under the aponeurosis of the su-
raspinatus forelimb muscles of the DMD-affected
ittermates.
Excisional muscle biopsies were obtained under
nesthesia before intramuscular bone marrow injec-
ion and 5, 9, and 15 weeks following injection. Injec-
ion sites were clearly identiﬁed by placement of non-
bsorbable monoﬁlament sutures. Clonal satellite cell
ultures were initiated from biopsies using myoblast
ulture techniques as previously described [11]; after 5
ays and with the initiation of myotube formation,
ultures were trypsinized and DNA extracted for anal-
sis of donor contributions using a variable number of
igure 2. Reverse-transcriptase-PCR reactions for dystrophin and
ystrophin mRNA expression above the background after intramusandem repeats-PCR method [15]. Six replicates werexamined for each biopsy, and no detectable donor
ontribution was observed (Figure 1). Consistent with
hese ﬁndings, immunoﬂuorescence (data not shown)
nd reverse-transcriptase (RT)-PCR (Figure 2) anal-
ses for dystrophin protein and mRNA expression,
espectively, failed to demonstrate increases over
ackground.
Our results in a relevant large animal model of
MD, made tolerant to the dystrophin protein, dem-
nstrate that, even in the absence of a requirement for
uscle speciﬁc homing, HCT does not contribute to
uscle regeneration. These ﬁndings lessen the enthu-
iasm for strategies relying on hematopoietic stem cell
ransdifferentiation to repair or regenerate skeletal
uscle.
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